Company: TAK
Filing Date: 2025-06-27
Form Type: 424B2
Source: 0001628280-25-033198
Chunk: 15

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-27
Form: 424B2
Chunk 15
---
 June 12, 2025, TPC completed the offering of its (i) ¥103.0 billion aggregate principal amount of 1.599% unsecured bonds due 2030, (ii) ¥41.0 billion aggregate principal amount of 1.935% unsecured bonds due 2032 and (iii) ¥40.0 billion aggregate principal amount of 2.292% unsecured bonds due 2035.

(2) Dollar amounts translated into yen have been translated at the rate of ¥149.90 = $1.00, the rate as of March 31, 2025 based on the noon buying rate in New York City for cable transfers in foreign currencies as certified for customs purposes by the Federal Reserve Bank of New York.

(3) On June 10, 2025, Takeda announced the disposal of 17,355,770 shares of its common stock held as treasury stock at a disposal price of ¥4,336 per share, or an aggregate total of ¥75.3 billion, to Takeda Group employees outside of Japan under Takeda’s Long-Term Incentive Plan (LTIP). The disposal date is scheduled to be July 8, 2025.

(4) Represents the sum of long-term debt and total equity.

Except as disclosed above, there has been no material change in Takeda’s consolidated capitalization and indebtedness since March 31, 2025.

<div align='center'>S-11</div>

### SELECTED FINANCIAL AND OTHER INFORMATION
The following table presents selected financial information as of and for the fiscal years ended March 31, 2021, 2022, 2023, 2024 and 2025, which is derived from Takeda’s consolidated financial statements as of and for the same periods. These financial statements are prepared in accordance with IFRS.

The consolidated financial statements of Takeda Pharmaceutical Company Limited and its subsidiaries included in Takeda’s most recent annual report on Form 20-F for the fiscal year ended March 31, 2025, which is incorporated herein by reference, have been audited in accordance with the standards of the Public Company Accounting Oversight Board (United States) by KPMG AZSA LLC, Takeda’s independent registered public accounting firm.

You should read the selected consolidated financial information presented below together with the information included in “Item 5. Operating and Financial Review and Prospects” and the audited consolidated financial statements